biotech

Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment
Two Harvard Biotech Entrepreneurs Are Creating The "Trojan Horse" Of Cancer Treatment
Forbes
biotech
cancer
Flag link:
When Will They Learn? 4 Huge Biotech Blowups
When Will They Learn? 4 Huge Biotech Blowups
Motley Fool
biotech
AstraZeneca
ZS-9
drug manufacturing
Alexion
Synageva
Merck
Cubist Pharmaceuticals
AbbVie
Rova-T
Stemcentrx
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
3 Biotech Stocks That Skyrocketed This Week
3 Biotech Stocks That Skyrocketed This Week
Motley Fool
biotech
Geron
imetelstat
Arena Pharmaceuticals
etrasimod
Heron Therapeutics
HTX-011
Flag link:
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
GoinPharma
biotech
FDA
Azedra
Progenics Pharmaceuticals
AbbVie
Rova-T
PharmaMar
Flag link:
NYC’s biotech scene gets cash and office space with Beacon’s new incubator
NYC’s biotech scene gets cash and office space with Beacon’s new incubator
Endpoints
NYC
biotech
Beacon Pharma
startups
Flag link:
This Biotech Stock Catapulted After Its Pain Drug Trumped A Key Rival
This Biotech Stock Catapulted After Its Pain Drug Trumped A Key Rival
Investors Business Daily
biotech
painkillers
Heron Pharmaceuticals
Pacira
HTX-011
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
Theranos and the Problem With Booming Biotech Funding
Theranos and the Problem With Booming Biotech Funding
Bloomberg
Theranos
biotech
diagnostics
SEC
fraud
Flag link:
Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis
biotech
Cellular Biomedicine
Flag link:
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
biotech
FDA
Flag link:
MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW
MasSpec Pen Wins Award In Health, Med, Biotech Category at SXSW
CP Wire
MasSpec Pen
devices
biotech
cancer surgery
cancer
SXSW
Flag link:
Biotech tries to break bread with Silicon Valley’s disruptors. It’s awkward
Biotech tries to break bread with Silicon Valley’s disruptors. It’s awkward
Stat
biotech
Silicon Valley
SXSW
Flag link:
3 Things In Biotech, March 8: A Tale Of 3 New Trials
3 Things In Biotech, March 8: A Tale Of 3 New Trials
Seeking Alpha
biotech
clinical trials
Seattle Genetics
SGN-CD48A
Daiichi Sankyo
DS-8201
HER-positive colorectal cancer
Allena Pharmaceuticals
hyperoxaluria
Flag link:
In Two Months, Biotech Startups Raised More Money Than In All Of 2013
In Two Months, Biotech Startups Raised More Money Than In All Of 2013
Forbes
biotech
startups
venture capital
Flag link:
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
Forbes
Celgene
biotech
FDA
RTF letters
ozanimod
Flag link:
On Rare Disease Day, recognizing the life and work of biotech giant Henri A. Termeer
On Rare Disease Day, recognizing the life and work of biotech giant Henri A. Termeer
Endpoints
Rare Diseases
Rare Disease Day
biotech
Henri Termeer
Genzyme
Sanofi
Flag link:
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug
Fierce Biotech
AstraZeneca
autoimmune disease
Viela Bio
spinoffs
biotech
Flag link:
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups
Xconomy
Quentis
biotech
startups
cancer
NYC
Flag link:
Grey Hair In the C-Suite: Experience, Age, And IPOs In Biotech
Grey Hair In the C-Suite: Experience, Age, And IPOs In Biotech
Forbes
biotech
executives
age
IPOs
Flag link:

Pages